Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

CYCN
Cyclerion Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jun 6, 2025 3:15:25 PM EDT
3.20USD+0.946%(+0.03)15,153
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 4, 2025 9:05:30 AM EDT
3.21USD+1.262%(+0.04)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
08:16AM EST  Cyclerion Therapeutics Announces Initiation Of Patient Dosing In CY6463 Phase 2a Study In Alzheimer's Disease With Vascular Pathology   Benzinga
08:00AM EST  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study in Alzheimers Disease with Vascular Pathology (ADv).   GlobeNewswire Inc
Nov 23, 2021
07:21AM EST  Cyclerion Therapeutics Granted U.S. Patent #11,180,493 'SGC stimulators'   Benzinga
Nov 11, 2021
05:32PM EST  Cyclerion Therapeutics to Participate in Jefferies London   GlobeNewswire Inc
Nov 9, 2021
05:03PM EST  Cyclerion Therapeutics Reports Q3 Net Loss Of ~$11.3M, Compared To $18.8M YoY   Benzinga
04:01PM EST  First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS)   GlobeNewswire Inc
Oct 20, 2021
10:14AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021   Benzinga
07:04AM EDT  Truist Securities Initiates Coverage On Cyclerion Therapeutics with Buy Rating, Announces Price Target of $14   Benzinga
Sep 24, 2021
10:43AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021   Benzinga
07:20AM EDT  Cantor Fitzgerald Initiates Coverage On Cyclerion Therapeutics with Overweight Rating, Announces Price Target of $7   Benzinga
Sep 22, 2021
08:06AM EDT  Cyclerion Therapeutics Highlights Publication Of Preclinical Data Showing Reduction In Neuroinflammation By Brain-Penetrant Soluble Guanlyate Cyclase Stimulator   Benzinga
08:00AM EDT  Cyclerion Announces Publication of Preclinical Data Demonstrating   GlobeNewswire Inc
Sep 8, 2021
08:00AM EDT  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences.   GlobeNewswire Inc
Aug 23, 2021
05:00PM EDT  Cyclerion Therapeutics to Present at Annual Biomarkers for   GlobeNewswire Inc
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 22, 2021
04:31PM EDT  Cyclerion Therapeutics Will Present Trial Design For CY6463 Phase 2a Study In Patients With Alzheimer's Disease With Vascular Pathology   Benzinga
12:39PM EDT  Cyclerion Therapetuics National Institutes Of Health ClinicalTrials.gov Study Record Detail For Co.'s 'Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia,' Shows Not Yet Recruiting   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
06:14AM EDT  Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers   Benzinga
Jul 8, 2021
07:23PM EDT  Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership   PR Newswire
04:32PM EDT  Cyclerion Therapeutics and Beacon Biosignals Announce Expanded   GlobeNewswire Inc
04:30PM EDT  Cyclerion Therapeutics, Beacon Biosignals Announce Expanded Strategic Partnership; Terms Not Disclosed   Benzinga
Jun 10, 2021
03:10PM EDT  Cyclerion Therapeutics Receives Decision To Grant European Patent 'Novel Processes For Preparation Of Soluble Guanylate Cyclase Stimulators'   Benzinga
Jun 8, 2021
09:17AM EDT  The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex   Benzinga
05:46AM EDT  Cyclerion Therapeutics CEO Peter Hecht Reported Purchase of 823,170 Shares @ Avg Price of $3.28/Share in Form 4 Filing on Monday   Benzinga
Jun 7, 2021
05:32PM EDT  Cyclerion Therapeutics Shares Volatile After Hours Following 2 Form 4 Filings; 1 Filing Shows Purchase Of ~961.5K Shares Of Common Stock Via 10% Holder, Slate Path Capital, 1 Filing By Co. CEO For ~823K Shares   Benzinga
Jun 4, 2021
10:27AM EDT  Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise   Benzinga
08:22AM EDT  Cyclerion Therapeutics Inc. (CYCN) said that it has reached a global license agreement with Akebia Therapeutics Inc., a biopharmaceutical company focused on kidney disease, for the development and commercialization of praliciguat, an oral sGC stimulator.   RTTNews
08:08AM EDT  Cyclerion Enters Exclusive, Global License Agreement With Akebia Therapeutics For Praliciguat   RTTNews
08:02AM EDT  Cyclerion Therapeutics Reports Global Licensing Deal With Akebia Therapeutics For Praliciguat; Co. Eligible For Up To $585M In Milestone Payments   Benzinga
08:01AM EDT  Cyclerion Therapeutics Reports $18M Private Placement With EcoR1 Capital, Slate Path Capital, MFN Partners, Invus, Lincoln Park Capital, Polaris Partners: ~5.74M Shares At $3.12/Share   Benzinga
08:00AM EDT  Cyclerion Therapeutics Announces $18 Million Private Placement   GlobeNewswire Inc
08:00AM EDT  Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties   GlobeNewswire Inc
May 27, 2021
04:33PM EDT  Cyclerion Therapeutics Highlights Publication Of CY6463 Preclinical Data In Frontiers In Pharmacology   Benzinga
04:30PM EDT  Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator   GlobeNewswire Inc
May 25, 2021
07:00AM EDT  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. Management will also be available for one-on-one meetings and investors may request a meeting through Jefferies.   GlobeNewswire Inc
May 8, 2021
12:10PM EDT  The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More   Benzinga
May 7, 2021
10:47AM EDT  Shares of Cyclerion Therapeutics, Inc. (CYCN) are rising more than 13% Friday morning at $2.83.   RTTNews
May 4, 2021
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 27, 2021
09:00AM EDT  Provided updates on development strategy and execution for CY6463, a first-in-class, CNS-penetrant sGC stimulator, including IND clearance from FDA in ADv and ongoing MELAS program   GlobeNewswire Inc
07:41AM EDT  The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout   Benzinga
Apr 26, 2021
07:00AM EDT  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced today the appointment of Errol De Souza, Ph.D., to its board of directors.   GlobeNewswire Inc
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Apr 21, 2021
07:30AM EDT  Cyclerion Therapeutics to Participate in the B. Riley Neuroscience   GlobeNewswire Inc
Apr 20, 2021
07:00AM EDT  Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS   GlobeNewswire Inc
Mar 24, 2021
04:11PM EDT  TransMedics Appoints Stephanie Lovell To Board Of Directors   RTTNews
Mar 19, 2021
07:46AM EDT  The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs   Benzinga
Mar 18, 2021
05:01PM EDT  Cyclerion Therapeutics Announces Departure Of Chief Medical Officer   Benzinga
Feb 25, 2021
07:39AM EST  Cyclerion Reports FY 2020 Net Loss $77.8M Vs $123M YoY   Benzinga
07:00AM EST  Novel mechanism of CY6463 demonstrated desired blood brain barrier penetration, target engagement, favorable safety and tolerability profile as well as evidence in multiple independent biomarkers associated with cognitive impairment, including neuroinflammatory biomarkers;   GlobeNewswire Inc
Feb 23, 2021
04:00PM EST  USPTO Site Shows Cyclerion Therapeutics Patent For 'Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators'   Benzinga
Jan 25, 2021
07:00AM EST  Leading experts in central nervous system (CNS) clinical development and translational sciences to advise companys advancement of therapeutic pipeline candidates   GlobeNewswire Inc
Jan 13, 2021
07:44AM EST  Cyclerion Therapeutics Reports Prelim. Unaudited Cash, Cash Equivalents And Restricted Cash Balance As Of Dec. 31, 2021 Was About $58M   Benzinga
Jan 4, 2021
07:00AM EST  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences:   GlobeNewswire Inc
Dec 21, 2020
07:34AM EST  Cyclerion Therapeutics Appoints Anjeza Gjino CFO, Current CEO to Help with Transition   Benzinga
07:30AM EST  Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor   GlobeNewswire Inc
Dec 8, 2020
05:54AM EST  Cyclerion Therapeutics Awarded U.S. Patent 10,858,363 "SGC stimulators"   Benzinga
05:32AM EST  Cyclerion Therapeutics Awarded Patent 10,858,363 "SGC stimulators"   Benzinga
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 5, 2020
07:17AM EST  Cyclerion Therapeutics Says Cash, Equivalents And Restricted Cash Balance On Sept. 30 Was ~$71M   Benzinga
07:00AM EST  Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant improvements in multiple measures associated with age-related cognitive decline and neurodegenerative diseases   GlobeNewswire Inc
Oct 14, 2020
02:33PM EDT  Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Allscripts Healthcare Solutions Shares Jump   Benzinga
12:13PM EDT  Mid-Day Market Update: Crude Oil Rises 1.5%; Cyclerion Therapeutics Shares Plummet   Benzinga
10:14AM EDT  Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Tops Q3 Expectations   Benzinga
10:07AM EDT  Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study   Benzinga
07:12AM EDT  Cyclerion Announces Data From IW-6463 CNS Translational Pharmacology Study In Healthy Elderly Subjects   Benzinga
07:11AM EDT  Cyclerion Announces Top-line Results From STRONG-SCD Study Of Olinciguat   RTTNews
07:09AM EDT  Cyclerion Therapeutics Says Phase 2 STRONG-SCD Study Results In Sickle Cell Disease 'did not demonstrate adequate activity to support further internal clinical development'   Benzinga
07:01AM EDT  Showedsignificant improvements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases   GlobeNewswire Inc
07:00AM EDT  Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients   GlobeNewswire Inc
Oct 1, 2020
07:33AM EDT  Cyclerion Says Expects To Communicate Top Line Results From Olinciguat Phase 2 Strong Study In Sickle Cell Disease Patients & IW-6463 Translational Pharmacology In The Coming Weeks   Benzinga
Sep 4, 2020
07:00AM EDT  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company management will be participating in several upcoming September 2020 investor conferences:   GlobeNewswire Inc
Aug 25, 2020
07:00AM EDT  Cyclerion Announces Translational Research Award from the   GlobeNewswire Inc
Aug 3, 2020
09:30AM EDT  Cyclerion Therapeutics Q2 Net Loss ~20M Vs. Loss ~$32M Last Year; Sales ~$700K Vs ~1.6M Last Year   Benzinga
09:25AM EDT  -IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively -   GlobeNewswire Inc
Jul 30, 2020
09:00AM EDT  -Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease-   GlobeNewswire Inc
Jul 17, 2020
07:00AM EDT  Cyclerion Therapeutics Presentation at Biomarkers in   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC